JP2018512164A5 - - Google Patents

Download PDF

Info

Publication number
JP2018512164A5
JP2018512164A5 JP2017554345A JP2017554345A JP2018512164A5 JP 2018512164 A5 JP2018512164 A5 JP 2018512164A5 JP 2017554345 A JP2017554345 A JP 2017554345A JP 2017554345 A JP2017554345 A JP 2017554345A JP 2018512164 A5 JP2018512164 A5 JP 2018512164A5
Authority
JP
Japan
Prior art keywords
composition
mutation
genes
subject
mutant allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017554345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512164A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/027773 external-priority patent/WO2016168612A1/en
Publication of JP2018512164A publication Critical patent/JP2018512164A/ja
Publication of JP2018512164A5 publication Critical patent/JP2018512164A5/ja
Pending legal-status Critical Current

Links

JP2017554345A 2015-04-15 2016-04-15 骨髄増殖性障害を処置するための方法 Pending JP2018512164A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562148005P 2015-04-15 2015-04-15
US62/148,005 2015-04-15
US201562218869P 2015-09-15 2015-09-15
US62/218,869 2015-09-15
PCT/US2016/027773 WO2016168612A1 (en) 2015-04-15 2016-04-15 Methods for treating myeloproliferative disorders

Publications (2)

Publication Number Publication Date
JP2018512164A JP2018512164A (ja) 2018-05-17
JP2018512164A5 true JP2018512164A5 (cg-RX-API-DMAC7.html) 2019-05-23

Family

ID=57127338

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017554345A Pending JP2018512164A (ja) 2015-04-15 2016-04-15 骨髄増殖性障害を処置するための方法

Country Status (9)

Country Link
US (1) US20180318303A1 (cg-RX-API-DMAC7.html)
EP (1) EP3283655A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018512164A (cg-RX-API-DMAC7.html)
CN (1) CN108138234A (cg-RX-API-DMAC7.html)
AU (1) AU2016248317A1 (cg-RX-API-DMAC7.html)
CA (1) CA2983004A1 (cg-RX-API-DMAC7.html)
HK (2) HK1256036A1 (cg-RX-API-DMAC7.html)
RU (1) RU2017139122A (cg-RX-API-DMAC7.html)
WO (1) WO2016168612A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
RU2020111934A (ru) 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
JP6852397B2 (ja) * 2016-12-28 2021-03-31 株式会社島津製作所 分析用試料の調製方法および分析方法
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018160397A1 (en) 2017-03-01 2018-09-07 The Board Of Trustees Of The Leland Stanford Junior University Highly specific circular proximity ligation assay
DE102017107661A1 (de) 2017-04-10 2018-10-11 Universität Rostock SH2B-Adapterprotein-3 für die Vorhersage einer Knochenmarkantwort und Immunantwort
AU2019227979B2 (en) 2018-03-02 2024-09-05 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
CN112770783B (zh) * 2018-07-31 2025-02-25 美国杰龙生物医药公司 鉴定可能从端粒酶抑制剂治疗中受益的患者的方法
KR101962869B1 (ko) * 2018-08-02 2019-03-27 주식회사 우리메디칼 이미지 분석에 기반한 골수판독 지원 장치
CA3117678A1 (en) * 2018-10-31 2020-05-07 Stemline Therapeutics, Inc. Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agents
CN119455003A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
IL328846A (en) * 2019-03-01 2026-08-01 Allogene Therapeutics Inc Constitutively active chimeric cytokine receptors and compounds comprising them for the treatment of cancer and autoimmune diseases
IL285941B1 (en) 2019-03-01 2026-08-01 Allogene Therapeutics Inc Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN
BR112022003553A2 (pt) 2019-08-30 2022-05-24 Allogene Therapeutics Inc Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN111471095B (zh) * 2020-01-15 2021-12-21 上海众启生物科技有限公司 用于阿尔茨海默症自身抗体检测的含jmjd2d蛋白片段的组合物
PE20221757A1 (es) 2020-02-24 2022-11-11 Allogene Therapeutics Inc Celulas t con car de bcma con actividades mejoradas
EP3900789A1 (en) * 2020-04-23 2021-10-27 Universitätsklinikum Jena Pharmaceutical combination for the treatment of myeloproliferative neoplasms
CN113549597B (zh) * 2021-07-22 2022-03-25 浙江大学 一种人原发性骨髓纤维化细胞株及其应用
CN114752575B (zh) * 2022-04-07 2023-06-13 内蒙古工业大学 一种nad+依赖性脱氢酶基因及其在提高辅酶q10产量中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
HUE041034T2 (hu) * 2009-06-17 2019-05-28 Promedior Inc SAP-variánsok és alkalmazásuk
RU2020111934A (ru) * 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака

Similar Documents

Publication Publication Date Title
RU2017139122A (ru) Способы лечения миелопролиферативных нарушений
RU2670070C2 (ru) Способ получения эритроцитов, нагруженных одним или несколькими веществами, представляющими фармацевтический интерес, и полученные таким образом эритроциты
JP2016539087A5 (cg-RX-API-DMAC7.html)
RU2016117775A (ru) Способы лечения фиброзного рака
JP6680760B2 (ja) アンタゴニストic pd−1アプタマー及びその癌治療関連用途への応用
WO2019213686A1 (en) Therapeutic compositions and uses therefor
JP2024521086A (ja) 血管作動性腸ペプチド(vip)受容体アンタゴニスト
CA3109702A1 (en) Peptides and compositions for targeted treatment and imaging
EP3813884B1 (en) In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
US20250319172A1 (en) Anticancer vaccine composition comprising hsp90 antigenic peptide and use thereof
WO2021051066A1 (en) Her3 pulsed dc1 therapy
US20220143179A1 (en) Drug delivery for combination of epigenetic modulation and immune checkpoint blockade
JP6702938B2 (ja) アンタゴニストic ctla−4アプタマー及びその免疫活性増強への応用
TW201924717A (zh) 活性調節劑
KR102191695B1 (ko) 전이 억제제
EP3323411A1 (en) Composition for inhibiting angiogenesis containing nanoparticle-vitreous body-based protein complex as active ingredient, and use thereof
US20210322508A1 (en) Peptides and compositions for targeted treatment and imaging
US12059434B2 (en) Short-term activated DC1s and methods for their production and use
WO2024081858A1 (en) Kras/tp53 neoantigen specific t cell receptors
CN116723863A (zh) 用于治疗出血性病症的组合物和方法
IL303089A (en) Compositions and methods for treatment of bleeding disorders
US20250302961A1 (en) Targeting myeloid-derived suppressor cells (mdscs) in bladder cancer to enhance efficacy of adoptive cell therapy (act)
KR20240033090A (ko) 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생
US20260102468A1 (en) Compositions and methods for marco inhibition and improved drug delivery
WO2024206078A2 (en) Liposomal compositions of archexin